Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study
第一作者机构:[1]Guangzhou Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
Liang W.,Jiang S.,Chai Y.,et al.Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study[J].ANNALS OF ONCOLOGY.2022,33(7):S1062-S1063.
APA:
Liang, W.,Jiang, S.,Chai, Y.,Liu, W.,Liu, L....&He, J..(2022).Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study.ANNALS OF ONCOLOGY,33,(7)
MLA:
Liang, W.,et al."Real-world adjuvant treatment patterns in patients with stage I-III EGFR-mutated non-small cell lung cancer (NSCLC) in China: Interim analysis from the ADDRESS study".ANNALS OF ONCOLOGY 33..7(2022):S1062-S1063